-

Verastem Oncology to Present at Upcoming Investor Conferences

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, today announced that management will present virtually at the following upcoming investor conferences:

  • H.C. Wainwright 22nd Annual Global Investment Conference on Monday, September 14, 2020 at 1:30 p.m. Eastern Time
  • Cantor Virtual Global Healthcare Conference on Thursday, September 17, 2020 at 3:20 p.m. Eastern Time

A live webcast of the presentations will be available on the investors section of the Company’s website at www.verastem.com. An archived presentation will be available for 90 days.

About Verastem Oncology

Verastem Oncology (Nasdaq: VSTM) is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and focal adhesion kinase (FAK) inhibition. For more information, please visit www.verastem.com.

Contacts

Verastem Oncology Contacts:

Investors:
John Doyle
Vice President, Investor Relations & Finance
+1 781-469-1546
jdoyle@verastem.com

Media:
Lisa Buffington
Corporate Communications
+1 781-292-4205
lbuffington@verastem.com

Industry:

Verastem Oncology

NASDAQ:VSTM
Release Versions
English

Contacts

Verastem Oncology Contacts:

Investors:
John Doyle
Vice President, Investor Relations & Finance
+1 781-469-1546
jdoyle@verastem.com

Media:
Lisa Buffington
Corporate Communications
+1 781-292-4205
lbuffington@verastem.com

More News From Verastem Oncology

Verastem Oncology Appoints Michael P. Bailey to its Board of Directors

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Michael P. Bailey to its Board of Directors. The Company also announced that Robert Gagnon stepped down from the Board following the end of his term on May 21, 2026. “We are excited to have Michael join our Board as he brings more than three decades of experience leading global pharmaceut...

Verastem Oncology to Present at Upcoming Investor Conferences

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate and present at the following investor conferences in New York City: HCW 4th Annual BioConnect Investor Conference: Tuesday, May 19, 2026, 4:00-4:30 pm ET RBC Global Healthcare Conference: Wednesday, May 20, 2026, 9:30-9:55 am ET A live webcast of the fire...

On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer

BOSTON--(BUSINESS WIRE)--Today, STAAR Low-Grade Serous Ovarian Cancer Foundation, Not These Ovaries, and Verastem Oncology announced the launch of the LGSOC Resource Guide, a unique resource designed to support patients living with low-grade serous ovarian cancer (LGSOC), a rare and distinct form of ovarian cancer, along with their caregivers and advocates. Available at www.LGSOCAwarenessDay.org, the guide launches in conjunction with World Ovarian Cancer Day, a global effort to raise awareness...
Back to Newsroom